Rgenta Therapeutics: Funding, Investors & Team (Nov 2026)
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Rgenta Therapeutics has raised $96.8M across 5 funding rounds on record, the most recent a Series B of $41.9M announced in Nov 2026.
That round is above the $8.8M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Rgenta Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2026.
Rgenta Therapeutics Funding Rounds
Rgenta Therapeutics raised $20.0M in an undisclosed round announced in Apr 2020.
1.1 years later, an undisclosed round of $18.0M was announced in May 2021.
9 months later, an undisclosed round of $8.9M was announced in Feb 2022.
1.3 years later, a Series A of $8.0M was announced in May 2023.
3.5 years later, a Series B of $41.9M was announced in Nov 2026.
Rgenta Therapeutics Investors
12 investors are recorded in total; the 5 named above are those the record identifies.
Rgenta Therapeutics Founders and Leadership Team
Contact details for the Rgenta Therapeutics team: 2 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Rgenta Therapeutics Funding Compared to Other Biotechnology Startups
Rgenta Therapeutics' latest round of $41.9M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Rgenta Therapeutics in Biotechnology and Cambridge
Companies Similar to Rgenta Therapeutics
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Rgenta Therapeutics Funding FAQs
What does Rgenta Therapeutics do?
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.
How much funding has Rgenta Therapeutics raised?
Rgenta Therapeutics has raised $96.8M across 5 rounds on record. The most recent is a Series B of $41.9M announced in Nov 2026.
When did Rgenta Therapeutics last raise funding?
Rgenta Therapeutics' most recent funding round on record is a Series B of $41.9M, announced in Nov 2026.
Who has invested in Rgenta Therapeutics?
Investors on record for Rgenta Therapeutics include Matrix Partners China, AstraZeneca, Highlight Capital, Vivo Capital, Legend Star. FundedIQ records 12 investors in total.
Who founded Rgenta Therapeutics?
FundedIQ lists Travis Wager (Founder) at Rgenta Therapeutics.
Who is the CEO of Rgenta Therapeutics?
Simon Xi is listed as CEO at Rgenta Therapeutics.
Where is Rgenta Therapeutics headquartered?
Rgenta Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Rgenta Therapeutics have?
Rgenta Therapeutics is in the 11-50 employee band.
When was Rgenta Therapeutics founded?
Rgenta Therapeutics was founded in 2020.
How does Rgenta Therapeutics' funding compare to other Biotechnology startups?
Rgenta Therapeutics' latest round of $41.9M is above the $8.8M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Rgenta Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Rgenta Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.